Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson’s Disease Mouse Model

Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson’s Disease Mouse Model

Parkinson’s disease (PD) is a chronic neurodegenerative disease. Type 2 diabetes mellitus (T2DM) has been identified as a risk factor for PD. Drugs originally developed for T2DM treatment such as liraglutide have shown neuroprotective effects in mouse models of PD. Cholecystokinin (CCK) is a peptide...

Full description

Bibliographic Details
Main Authors: Zijuan Zhang, Hai Li, Yunfang Su, Jinlian Ma, Ye Yuan, Ziyang Yu, Ming Shi, Simai Shao, Zhenqiang Zhang, Christian Hölscher
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Neuroscience
Subjects:
Parkinson’s disease
CCK
insulin
MPTP
neuroinflammation
apoptosis
Online Access:https://www.frontiersin.org/articles/10.3389/fnins.2022.814430/full

Internet

https://www.frontiersin.org/articles/10.3389/fnins.2022.814430/full

Similar Items